Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04895358
Title Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

Her2-receptor negative breast cancer

Therapies

Nab-paclitaxel

Nab-paclitaxel + Pembrolizumab

Capecitabine + Pembrolizumab

Paclitaxel + Pembrolizumab

Capecitabine

Daunoxome + Pembrolizumab

Daunoxome

Paclitaxel

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | AUT


No variant requirements are available.